Methadone Alkaloid

Methadone, the active ingredient in Methadone Alkaloid, is a synthetic opioid presented as an oral dosage form for oral use. It is used to treat opioid dependence and manage chronic pain in adults.

GNH USA supplies Methadone Alkaloid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methadone is employed in the management of opioid‑related disorders and pain syndromes. - Opioid dependence: suppresses withdrawal symptoms and supports maintenance therapy. - Chronic pain: provides long‑acting analgesia for severe, persistent pain. - Opioid use disorder: reduces cravings and stabilises opioid receptors.

Methadone may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Constipation: reduced bowel motility. - Drowsiness: increased sedation, especially at treatment initiation. - Dry mouth: reduced salivary flow. - Sweating: excessive perspiration. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Respiratory depression: marked reduction in breathing rate. - QT interval prolongation: risk of cardiac arrhythmia. - Severe hypotension: dangerous drop in blood pressure. - Seizures: rare convulsive episodes. - Allergic reactions: rash, itching, or anaphylaxis. - Dependence or misuse: potential for abuse with prolonged use.

Methadone requires careful monitoring due to its potency and pharmacologic profile. - Initiation: start at low dose and titrate slowly under medical supervision. - Cardiac monitoring: obtain baseline ECG and monitor QT interval. - Concomitant CNS depressants: avoid or use with caution to reduce respiratory risk. - Pregnancy: assess risk‑benefit; methadone is Category C. - Breastfeeding: weigh infant exposure against maternal benefit. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Methadone interacts with several drug classes that can alter its efficacy or safety.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole): may increase methadone levels and risk of toxicity. - QT‑prolonging agents (e.g., quinidine): additive risk of cardiac arrhythmia. - CNS depressants (e.g., benzodiazepines): synergistic respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce methadone concentrations. - Antidepressants (e.g., SSRIs): can affect methadone metabolism. - Antiretrovirals (e.g., protease inhibitors): may alter plasma levels.